| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Optimi Health Corp. Common Shares
$4.83
-0.02 (-0.41%)
Market Cap
27.66 M
EPS
-
P/E Ratio
-
Value Trade
64.60 K
-2.62 %
Week
-1.63 %
1 Month
-5.11 %
3 Month
-20.56 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
2.42 K
52 Week Range
-
% held by Insiders
19.32 %
% held by Institutions
7.75 %
Enterprise Value
-
Total Shares
5.73 M
Short %
0.44 %
Float Shares
4.62 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Optimi Health Corp. Common Shares
24Total events
11Upcoming
2Tier-1 (high impact)
2025 – 2027Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
▲Manufacturing MilestoneCMC / Inspection
Subscribe to view catalyst details
TBD
●Management ChangeCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
OPTH Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OPTH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OPTH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-OPTH
Sep 29, 2026▼ -0.4%today
Optimi Health Appoints Melanie Pump to Board of Directors
Optimi Health Corp. has appointed Melanie Pump to its Board of Directors, bringing over 25 years of financial expertise. Pump's experience in technology and growth companies is expected to enhance Optimi's strategic direction in the psychedelic pharmaceutical market. The company also announced the resignation of Leah Hodges as Corporate Secretary, with CEO Dane Stevens taking over the role.
Read more →-OPTH
Sep 23, 2026Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
Optimi Health Corp. has completed the production of 5mg psilocybin capsules for a Phase 2 clinical trial approved by Health Canada, aimed at treating major depressive disorder (MDD). The trial will involve up to 200 participants, with dosing expected to conclude by the end of 2027. The same batch will also supply licensed clinics in Australia for treatment-resistant depression. Despite the progress, no psilocybin products have received market authorization yet.
Read more →-OPTH
Sep 22, 2026Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
Optimi Health Corp. has appointed Dr. Michael Blough as Chief Clinical Development Officer. Dr. Blough will oversee the company's clinical development strategy, including upcoming Phase 2 and Phase 3 trials for psilocybin and MDMA-assisted therapies. His extensive experience with Health Canada and psychedelic trials positions him to advance these critical studies.
Read more →-OPTH
Sep 16, 2026Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder
Optimi Health Corp. plans to launch a Phase 3 clinical trial for MDMA-assisted therapy aimed at treating post-traumatic stress disorder (PTSD). The trial, expected to start in 2027, will involve up to 100 participants, primarily veterans and frontline workers. The study will assess the therapy's efficacy using the Clinician-Administered PTSD Scale. Despite the promise of psychedelic-assisted therapies, the safety and efficacy of MDMA for PTSD remain under investigation.
Read more →-OPTH
Sep 10, 2026Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
Optimi Health Corp. plans to initiate a Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD) in 2027. The trial will involve up to 200 participants across Canada and aims to assess the safety and efficacy of a single supervised dose of natural psilocybin. This study represents a significant commitment for Optimi, which will utilize its own manufactured psilocybin and aims for exclusive ownership of the trial results.
Read more →-OPTH
Sep 8, 2026Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Optimi Health Corp. (Nasdaq: OPTH) will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The company will provide a presentation on demand starting September 11, and management will be available for one-on-one meetings. Optimi specializes in manufacturing GMP-grade psychedelic drug products for mental health therapies.
Read more →-OPTH
Aug 14, 2026Optimi Health Establishes Discretionary Equity Facility
Optimi Health Corp. has established a discretionary equity line of credit with Seven Knots, allowing the company to sell up to $100 million in common shares. The agreement includes convertible promissory notes and is subject to market conditions and regulatory approvals. This move aims to bolster the company's financial flexibility as it continues to manufacture psychedelic drug products for mental health therapies.
Read more →-OPTH
Jun 29, 2026▲ +8.8%on this news· ran to +24% by day 1
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi Health Corp. has completed its third export of 5mg psilocybin capsules to Australia for patients with treatment-resistant depression. The capsules are prescribed under Australia's Authorized Prescriber Scheme, which has expanded access to psilocybin as a treatment. Optimi's production is fully compliant with Health Canada regulations, and the company reports no serious adverse events since the product's launch.
Read more →-OPTH
Jun 16, 2026▼ -12.9%on this news
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Optimi Health has launched two new microdose psilocybin products, available in 1mg and 2mg dosages, aimed at clinical research organizations. These products provide consistent, validated doses, addressing variability in traditional microdosing methods. The company continues to expand its psilocybin offerings, which are already prescribed for treatment-resistant depression in Australia.
Read more →-OPTH
Jun 10, 2026Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health Corp. has completed its first export of psilocybin to the UK to support a Phase 2 clinical trial. The shipment includes psilocybin biomass and 5mg capsules, which are already used in Australia for treatment-resistant depression. The company plans to announce its trial partner and indication later. This export positions Optimi as a key player in regulated psychedelic research.
Read more →-OPTH
Jun 8, 2026▲ +11.2%on this newsshared move
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health Corp. has secured a supply of ibogaine and is set to begin development of finished drug products at its GMP facility in British Columbia. The U.S. Executive Order prioritizing ibogaine for FDA review has heightened interest in its therapeutic potential for conditions like PTSD and opioid use disorder. The company plans to offer ibogaine in two dosage forms, 50mg and 100mg, and aims to standardize pharmaceutical dosages.
Read more →-OPTH
Jun 2, 2026Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi Health Corp. has successfully completed a GMP production run of its 5mg psilocybin capsules, which are prescribed for treatment-resistant depression in Australia. The company plans to use additional products from this run for clinical trials in the US and Europe. Optimi's facility is fully compliant with Health Canada regulations, allowing for secure production and distribution of psychedelic drug products.
Read more →-OPTH
May 29, 2026▲ +5.6%on this newsshared move
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
Optimi Health Corp. has welcomed the Therapeutic Goods Administration's updated framework in Australia, which expands access to psychedelic-assisted therapy. The new guidelines broaden therapist eligibility and treatment settings, reinforcing Australia's position as a leader in this field. Importantly, no serious adverse events have been reported since the program's inception, supporting further expansion.
Read more →-OPTH
May 29, 2026▲ +5.6%on this newsshared move
OPTIMI HEALTH CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS Overview This management's discussion and analysis (" MD&A ") relates to the operations and financial condition of Optimi Health Corp. (" Optimi " or the " Company
Optimi Health Corp. provided a detailed management discussion and analysis of its financial condition and operations as of May 29, 2026. The company highlighted its licensing under Health Canada for the production of psilocybin and MDMA, enabling it to supply these substances under strict regulatory frameworks. Notably, Optimi has engaged in a distribution agreement with Mind Medicine Australia, facilitating access to its products in the Australian market. The discussion also outlined ongoing investments in research and development to enhance production methodologies.
Read more →-OPTH
May 26, 2026Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia's Auth
Optimi Health Corp. has achieved a milestone by producing the highest-purity natural psilocybin extract to date, which contains 6% psilocybin. This advancement supports their efforts in supplying psilocybin products in Australia for patients with treatment-resistant depression under the Authorized Prescriber Scheme. The company maintains a diverse library of over 200 mushroom genetics, allowing continuous improvement in psilocybin content through optimized cultivation and extraction processes. Optimi's products are also set to aid clinical research in Europe, with a focus on providing finished drug products for various therapeutic programs.
Read more →Competitive Position
How OPTH ranks across every disease it competes inCompetitive Position is a premium feature
See how OPTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial